MULTIPLE MYELOMA

Latest News

FDA Grants OPN-6602 Orphan Drug Status in R/R Myeloma
FDA Grants OPN-6602 Orphan Drug Status in R/R Myeloma

February 17th 2025

The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.

Idecabtagene Vicleucel Shows Strong Response in Multiple Myeloma
Idecabtagene Vicleucel Shows Strong Response in Multiple Myeloma

February 17th 2025

Navigating the Use of Bispecific Antibodies and CAR T-Cell Therapy in RRMM
Navigating the Use of Bispecific Antibodies and CAR T-Cell Therapy in RRMM

February 17th 2025

Ciltacabtagene Autoleucel Improves Outcomes in Multiple Myeloma
Ciltacabtagene Autoleucel Improves Outcomes in Multiple Myeloma

February 15th 2025

Managing BsAb-Associated AEs in a Community Setting
Managing BsAb-Associated AEs in a Community Setting

February 13th 2025

More News